The South Korean clinical experts issued advices each on anti-COVID-19 antiviral drug (remdesivir, hydroxychloroquine, lopinavir, ritonavir and favipiravir), steroid, interleukin inhibitor, interferon, convalescent plasma therapy and general intravenous immunoglobulin.

For antibody treatments with social issues, such as Rekirona, the experts are currently reviewing literature, and planning to update the guideline every month.

National Evidence-based Healthcare Collaborating Agency (NECA) and Korean Society of Infectious Diseases (KSID) co-published a latest RWE-based clinical treatment guideline for treating COVID-19 patients with the said details.

An Ebola treatment remdesi